INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01367457
First received: June 3, 2011
Last updated: September 8, 2014
Last verified: September 2014
  Purpose

The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.


Condition Intervention
Carcinoma, Renal Cell
Lymphoma, Mantle-Cell
Other: Temsirolimus (Non-Interventional Study)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: January 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients that received treatment with Temsirolimus
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Other: Temsirolimus (Non-Interventional Study)
There is not any intervention in this study.

Detailed Description:

There is not sampling method

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.

Criteria

Inclusion Criteria:

Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.

Exclusion Criteria:

Patients that do not have a minimum (pre-specified) of data in their clinical record.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01367457

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
Spain
Hospital Universitario Central de Asturias Recruiting
Oviedo, Asturias, Spain, 33006
Hospital de Cabueñes Recruiting
Cabueñes, Gijon, Spain, 33394
Hospital Clinico Universitario Recruiting
Santiago de Compostela, La Coruña, Spain, 15706
Complejo Hospitalario Materno-Infantil Insular de Las Palmas Recruiting
Las Palmas de Gran Canaria, Las Palmas, Spain, 35016
Hospital de Navarra Recruiting
Pamplona, Navarra, Spain, 31008
Hospital Provincial de Castellon Recruiting
Castellon, Valencia, Spain, 12002
Complexo Hospitalario Universitario A Coruña Recruiting
A Coruña, Spain, 15006
Complejo AAsistencial de Avilla Recruiting
Avila, Spain, 05004
Hospital de La Santa Creu I Sant Pau Recruiting
Barcelona, Spain, 08025
Hospital Vall D'Hebron Recruiting
Barcelona, Spain, 08035
Hospital del Mar Recruiting
Barcelona, Spain, 8940
Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera Recruiting
La Coruña, Spain, 15006
Hospital Universitario La Paz Recruiting
Madrid, Spain, 28046
Hospital General Universitario Gregorio Marañon Recruiting
Madrid, Spain, 28007
MD Anderson Cancer Center Recruiting
Madrid, Spain, 28033
Hospital de Madrid Norte - Sanchinarro Recruiting
Madrid, Spain, 28050
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01367457     History of Changes
Other Study ID Numbers: B1771017, INHIBITOR
Study First Received: June 3, 2011
Last Updated: September 8, 2014
Health Authority: Spain: Comité Ético de Investigación Clínica

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Sirolimus
Everolimus
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors

ClinicalTrials.gov processed this record on September 14, 2014